Anticancer Res

1. YANISHI M, Shimada S, Mishima T, Kinoshita H, et al
   Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer.
   Anticancer Res. 2026;46:2145-2151.
   

   >> Share

   
   
2. WATANABE R, Shigehisa R, Kawada T, Yamamoto S, et al
   Paired-sample Analysis of ERG Expression and TMPRSS2-ERG Fusion in Treatment-induced Neuroendocrine Prostate Cancer.
   Anticancer Res. 2026;46:1929-1942.
   

   >> Share

   
   

   
   BJU Int

3. SUSHENTSEV N, Warren AY, Colling R, Verrill C, et al
   Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.
   BJU Int. 2026 Mar 27. doi: 10.1111/bju.70261.
   

   >> Share

   
   

   
   BMC Urol

4. ZHANG J, Chen J, Jin J, Chen J, et al
   Added value of systematic biopsy in patients with positive MRI-US fusion targeted biopsy for clinically significant prostate cancer: a single-center retrospective study.
   BMC Urol. 2026 Mar 27. doi: 10.1186/s12894-026-02123.
   

   >> Share

   
   

   
   Eur J Radiol

5. ZENG Y, Shen S, Ma H, Yin R, et al
   Early prediction via PET/CT for skeletal-related events in osteoporotic men with metastatic prostate cancer undergoing androgen deprivation therapy.
   Eur J Radiol. 2026;199:112822.
   

   >> Share

   
   

   
   Eur Radiol

6. SMITH H, Stavrinides V, Giganti F, Moore CM, et al
   Reply to the Letter to the Editor: Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
   Eur Radiol. 2026 Apr 2. doi: 10.1007/s00330-026-12492.
   

   >> Share

   
   
7. WANG Z, Yu C
   Letter to the Editor: Variation in prostate cancer growth rates in an MRI-based active surveillance cohort.
   Eur Radiol. 2026 Apr 1. doi: 10.1007/s00330-026-12488.
   

   >> Share

   
   

   
   Eur Urol

8. KHAN S, Papa N, Kneebone A, Eade T, et al
   Prospective Comparison of (64)Copper [(64)Cu]SAR-bisPSMA vs (68)Gallium[(68)Ga] PSMA-11 PET/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial).
   Eur Urol. 2026 Mar 27:S0302-2838(26)02035-X. doi: 10.1016/j.eururo.2026.
   

   >> Share

   
   
9. MONTIRONI R, Giannarini G, Cimadamore A, Lopez-Beltran A, et al
   Re: European Study of Prostate Cancer Screening - 23-Year Follow-up.
   Eur Urol. 2026 Mar 30:S0302-2838(26)02048-8. doi: 10.1016/j.eururo.2026.
   

   >> Share

   
   

   
   Int J Cancer

10. MATOS B, Monteiro MV, Lagarto MR, Howl J, et al
    Screening anticancer peptides performance in organotypic prostate tumor-stroma 3D models.
    Int J Cancer. 2026;158:2936-2946.
    

    >> Share

    
    

    
    Int J Urol

11. SATO Y, Fujii Y, Kume H
    Cancer Genomic Medicine for Urological Malignancies in Japan.
    Int J Urol. 2026;33:e70449.
    

    >> Share

    
    

    
    J Clin Oncol

12. ARMSTRONG AJ, Azad AA, Iguchi T, Stenzl A, et al
    Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2026 Mar 27:JCO2402829. doi: 10.1200/JCO-24-02829.
    

    >> Share

    
    

    
    J Nucl Med

13. ELLS Z, Meyer C, Kimura K, Wilhalme H, et al
    Dosimetry Analysis of (177)Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
    J Nucl Med. 2026 Apr 2:jnumed.125.271467. doi: 10.2967/jnumed.125.271467.
    

    >> Share

    
    

    
    Lancet Oncol

14. ALONGI F, Alongi P
    Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer.
    Lancet Oncol. 2026;27:400-402.
    

    >> Share

    
    
15. PRIVE BM, Noordzij W, Muselaers CHJ, de Jong IJ, et al
    [(177)Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.
    Lancet Oncol. 2026;27:461-469.
    

    >> Share

    
    
16. SANDHU S, Joshua AM, Emmett L, Bressel M, et al
    [(177)Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
    Lancet Oncol. 2026;27:470-479.
    

    >> Share

    
    

    
    Nat Rev Urol

17. CHEN DM, Blum KA, Hu JC
    Evidence for metastasis-directed therapy in oligometastatic prostate cancer.
    Nat Rev Urol. 2026 Apr 3. doi: 10.1038/s41585-026-01139.
    

    >> Share

    
    

    
    Oncogene

18. WEI X, Li X, Pan Y, Zhang Y, et al
    LDHA-driven lactate metabolism promotes MDSC activation and immunosuppressive microenvironment in prostate cancer.
    Oncogene. 2026 Apr 1. doi: 10.1038/s41388-026-03737.
    

    >> Share

    
    
19. LI N, Zoubeidi A, Beraldi E, Gleave ME, et al
    Editorial Expression of Concern: GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.
    Oncogene. 2026 Mar 30. doi: 10.1038/s41388-026-03770.
    

    >> Share

    
    

    
    PLoS One

20. YUAN X, Chen Y, Lu H, Zheng P, et al
    A survivorship-oriented enhanced care model for patients undergoing radical prostatectomy.
    PLoS One. 2026;21:e0346609.
    

    >> Share

    
    

    
    Prostate

21. OZLU DN, Arikan Y, Emir B, Ayten A, et al
    Development of Machine Learning Models for Predicting Prostate Cancer in Biopsy Candidates Using Prostate-Specific Antigen, Magnetic Resonance Imaging, and Hematologic Parameters.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70168.
    

    >> Share

    
    
22. SKOWRON AT, Childers K, Rose CM, McElyea KC, et al
    Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70165.
    

    >> Share

    
    
23. ONAL C, Elmali A, Demirhan B, Senturk E, et al
    Impact of Intraprostatic Simultaneous Integrated Boost on Long-Term Outcomes in Unfavorable Intermediate-Risk Prostate Cancer Treated With Dose-Escalated Radiotherapy and Short-Term Androgen Deprivation Therapy.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70167.
    

    >> Share

    
    
24. BAUER N, Fankhauser CD, Sigg S, Kaufmann E, et al
    Toward a Modern Telehealth Follow-Up Routine for Radical Prostatectomy: Introducing a Novel E-Health Application for Outcome and Complication Assessment.
    Prostate. 2026;86:718-726.
    

    >> Share

    
    
25. DARBANDI S, Urbanucci A, Hakkola S, Gujral J, et al
    Happening in the Prostate Tumor Microenvironment: Ion Channels and Extrachromosomal DNA Driving Phenotypic Plasticity.
    Prostate. 2026;86:619-636.
    

    >> Share

    
    
26. DOBREV H
    The Sign of Leser-Trelat as a Possible Indicator of Prostate Adenocarcinoma: A Case Report.
    Prostate. 2026;86:732-734.
    

    >> Share

    
    
27. OZAWA Y, Moschovas MC, Sandri M, Sharma R, et al
    Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates.
    Prostate. 2026;86:637-647.
    

    >> Share

    
    
28. TAYLOR KG, Johannessen B, Mills IG, Rye MB, et al
    Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70164.
    

    >> Share

    
    
29. HAN X, Zhao X, Zhang N, Yang D, et al
    Global Trends in Prostate Cancer Incidence Among Men Aged 55+ (1992-2021): An Age-Period-Cohort Analysis.
    Prostate. 2026 Mar 30. doi: 10.1002/pros.70166.
    

    >> Share

    
    
30. KUROKAWA K, Yamamoto S, Yamada Y, Sato K, et al
    A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2026 Mar 31. doi: 10.1002/pros.70171.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

31. HOLZGREVE A, Calais J
    Virchow Node in Prostate Cancer.
    Radiol Imaging Cancer. 2026;8:e250681.
    

    >> Share

    
    

    
    Radiology

32. GHODSI A, Owens L, Demirci RA, Gafita A, et al
    PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving (177)Lu-PSMA-617.
    Radiology. 2026;318:e250649.
    

    >> Share

    
    

    
    Ther Adv Urol

33. SANYAL C, Rendon R
    Cost-effectiveness of PSMA-PET imaging technology in diagnosing and staging of prostate cancer: a systematic review.
    Ther Adv Urol. 2026;18:17562872261436874.
    

    >> Share

    
    

    
    Urol Int

34. SCHOSTAK M, Peklo E, Peters I, Machtens S, et al
    Parameters predicting Recurrence after Focal Therapy for Prostate Cancer: Insights from a Multicenter Surveillance Database.
    Urol Int. 2026 Apr 2:1-20. doi: 10.1159/000551632.
    

    >> Share

    
    
35. ELLEISY M, Resch I, Yurdakul O, Hubner NA, et al
    Acute Kidney Injury in a Cancer Patient Exposed to Relugolix and Abiraterone.
    Urol Int. 2026;110:198-201.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share